SCHEMBL16616388

SCHEMBL16616388

CC(=O)c1cccnc1Nc1ccc(Cl)cc1

nearest known ligand 0.76

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.76
MEN1 O00255 7/20 0.76
KMT2A Q03164 7/20 0.76
DHODH Q02127 5/20 0.76
SMN1; SMN2 Q16637 4/20 0.76
NPC1 O15118 5/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
MAPT P10636 5/20 0.57
AHR P35869 1/20 0.57
ALDH1A1 P00352 4/20 0.56
GAA P10253 2/20 0.56
NPSR1 Q6W5P4 2/20 0.55
HTT P42858 1/20 0.55
MAPK1 P28482 1/20 0.52
LMNA P02545 1/20 0.51
TSHR P16473 1/20 0.51
KDR P35968 1/20 0.50
HPGD P15428 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9469395 0.86 DHODH (1.00) RAB9AMEN1KMT2ADHODHSMN1; SMN2
SCHEMBL16627429 0.86 MAPT (0.58) RAB9AMEN1KMT2ADHODHSMN1; SMN2
SCHEMBL846930 0.86 DHODH (0.76) RAB9AMEN1KMT2ADHODHSMN1; SMN2
SCHEMBL9469649 0.85 MEN1 (0.72) RAB9AMEN1KMT2ADHODHSMN1; SMN2
SCHEMBL29898323 0.85 RAB9A (0.76) RAB9AMEN1KMT2ADHODHSMN1; SMN2
SCHEMBL28824933 0.85 RAB9A (0.76) RAB9AMEN1KMT2ADHODHSMN1; SMN2
SCHEMBL16616643 0.85 DHODH (0.76) RAB9AMEN1KMT2ADHODHSMN1; SMN2
SCHEMBL16616153 0.84 MEN1 (0.62) RAB9AMEN1KMT2ADHODHSMN1; SMN2
SCHEMBL16616459 0.82 MEN1 (0.80) RAB9AMEN1KMT2ADHODHSMN1; SMN2
SCHEMBL12478838 0.81 RAB9A (0.65) RAB9AMEN1KMT2ADHODHSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9006451-B1 2-anilinonicotinyl based chalcones useful as potential anticancer agents and process for preparation thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-04-14 US disclosed
US-20150099888-A1 2-Anilinonicotinyl Based Chalcones Useful As Potential Anticancer Agents and Process for Preparation Thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-04-09 US disclosed
US-20150099888-A1 2-Anilinonicotinyl Based Chalcones Useful As Potential Anticancer Agents and Process for Preparation Thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099888-A1 2-Anilinonicotinyl Based Chalcones Useful As Potential Anticancer Agents and Process for Preparation Thereof HCCS, WEE2, WEE1 RAB9A 1415/4885MEN1 2511/4885KMT2A 2973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.